University of Washington, University of Texas Medical School Branch and Kineta Inc. Granted $8.1 Million for Biodefense Antiviral Drug Development

SEATTLE--(BUSINESS WIRE)--In collaboration with the University of Washington and the University of Texas Medical Branch at Galveston, Seattle-based biotech company, Kineta, Inc. announced a new $8.1 million biodefense grant to develop new drugs to treat some of the world’s most dangerous diseases, including Ebola, plague, Japanese encephalitis, and other lethal pathogens.